Abstract
Cannabinoids have been shown to increase neurogenesis in adult brain, as well as protect neurons from excitotoxicity, calcium influx, inflammation, and ischemia. Recent studies have shown that synthetic cannabinoids can alleviate water maze impairments in rats treated with intracranial amyloid β protein (Aβ); however it is unknown whether this effect is due to the cannabinoids anti-inflammatory properties or whether it affects Aβ processing. Here we investigate whether cannabinoids have any effect on Alzheimers disease in vivo. We found that HU210, a potent synthetic cannabinoid, did not improve water maze performance or a contextual fear conditioning task in an APP23/PS45 double transgenic mouse model of AD. HU210 had no effect on APP processing and Aβ generation, as well as neuritic plaque formation in the brains of AD transgenic mice. Our study showed that synthetic cannabinoid HU210 had no beneficial effects on AD neuropathology and behavioral deficits of AD model mice, which advises caution of such drugs application in AD therapies.
Keywords: Cannabinoids, HU210, memory deficits, Aβ, neurogenesis, Alzheimer
Current Alzheimer Research
Title: Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Volume: 7 Issue: 3
Author(s): B. Chen, K. Bromley-Brits, G. He, F. Cai, X. Zhang and W. Song
Affiliation:
Keywords: Cannabinoids, HU210, memory deficits, Aβ, neurogenesis, Alzheimer
Abstract: Cannabinoids have been shown to increase neurogenesis in adult brain, as well as protect neurons from excitotoxicity, calcium influx, inflammation, and ischemia. Recent studies have shown that synthetic cannabinoids can alleviate water maze impairments in rats treated with intracranial amyloid β protein (Aβ); however it is unknown whether this effect is due to the cannabinoids anti-inflammatory properties or whether it affects Aβ processing. Here we investigate whether cannabinoids have any effect on Alzheimers disease in vivo. We found that HU210, a potent synthetic cannabinoid, did not improve water maze performance or a contextual fear conditioning task in an APP23/PS45 double transgenic mouse model of AD. HU210 had no effect on APP processing and Aβ generation, as well as neuritic plaque formation in the brains of AD transgenic mice. Our study showed that synthetic cannabinoid HU210 had no beneficial effects on AD neuropathology and behavioral deficits of AD model mice, which advises caution of such drugs application in AD therapies.
Export Options
About this article
Cite this article as:
Chen B., Bromley-Brits K., He G., Cai F., Zhang X. and Song W., Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050948
DOI https://dx.doi.org/10.2174/156720510791050948 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Antioxidants and its Properties as Affected by Extrusion Process: A Review
Recent Patents on Food, Nutrition & Agriculture Medicinal Value and Potential Therapeutic Mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview
Current Topics in Medicinal Chemistry The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health
Current Medicinal Chemistry Non-Cholinergic Pharmacotherapy Approaches to Alzheimers Disease: The Use of Non-Steroidal Anti-Inflammatory Drugs
CNS & Neurological Disorders - Drug Targets New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimers Disease?
Current Alzheimer Research Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Benefit of 13-desmethyl Spirolide C Treatment in Triple Transgenic Mouse Model of Alzheimer Disease: Beta-Amyloid and Neuronal Markers Improvement
Current Alzheimer Research Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design A Review on Melatonin’s Effects in Cancer: Potential Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal